Izotropic Corporation | Izotropic Engages Mr. James Berard for Investor Relation Services

Izotropic Engages Mr. James Berard for Investor Relation Services


VANCOUVER, BC – June 4, 2020 – Izotropic Corporation (“Izotropic” or the “Company”) (CSE: IZO) (OTC US: IZOZF) (FSE: 1R3) is pleased to announce that it has entered into a consulting agreement with James Berard to provide investor relations and communication services and introduce financial professionals to the Company.

James has spent the past 17 years working in the public markets as an investor relations consultant with a number of companies including 3 years with Marketsmart Communications (marketsmart.ca) and Kcrew Communications.

During this period he has developed a network of retail investors, brokers, newsletter writers and financial professionals and is a welcome addition to the Company.

The initial term of the agreement is for six (6) months with a monthly fee of $4000.00.

The Company also announces a grant of 100,000 stock options to Mr. Berard at an exercise price of $0.17. The stock option is effect for 2 years and vests immediately.


Robert Thast
Chief Executive Officer


About Izotropic Corp.
Izotropic Corporation and its wholly owned U.S. operating subsidiary, Izotropic Imaging Corp. have been established to commercialize the next generation of breast imaging technology for early diagnosis of breast cancer. The Izotropic Breast CT Imaging System produces high resolution breast images in 3D. A single 10 second breast CT scan acquires approximately 500 images, without painful breast compression, providing radiologists with fully 3D viewing of the scanned breast. Mammography scanning requires compression of the breast between 2 imaging plates, resulting in 2D images.

The Company has the exclusive worldwide license from the University of California, Davis (UC Davis) to commercialize the technology developed by principal founder and Company director Dr. John M. Boone and researchers at UC Davis. The license includes all intellectual property, trade secrets, patents and patent-pending applications that are the foundation of the Company’s breast CT imaging platform.

Approximately $20 million in research funding and over 15 years of research and development have been invested in developing this groundbreaking breast CT imaging technology. Research includes a current, ongoing $2.9M U.S. clinical trial at UC Davis Medical Center.

The Company founders believe that this technology will be a disruptive entry to the market, overcoming many of the challenges faced by existing breast imaging modalities.

Phone: 1-833-IZOCORP
Email: info@izocorp.com
Website: izocorp.com